Abstract
Aim The aim of the study was to investigate the role of genetic variants in young patients (aged <50 years) with myocardial infarction (MI) and a family history of premature atherosclerosis.
Methods and Results The studied group consisted of 70 patients aged 26-49 (mean 43.1, SD ±4.3), 17 women and 53 men, with MI and with a family history of premature atherosclerosis, defined as MI or ischaemic stroke in first-degree relatives at age <65 years in women or <55 years in men. The total DNA was extracted from the peripheral blood samples. The targeted enrichment library was prepared and analyzed using the Next-Generation Sequencing method. Statistical analyses were performed using the R software package (http://www.r-project.org/). The results of sequencing were compared to data from the reference control population consisting of 597 people with no history of MI (418 women, 179 men) aged 18-83 (mean 40.5, SD ± 12.4) as a whole and after matching with a studied group by age and gender in a proportion 1:3 (210 people, 51 women, 159 men, aged 18-77, mean 42.1, SD ±10.6) using Propensity Score Matching. Risks associated with detected variants were evaluated using Fisher’s exact test based on the allelic frequencies of variants in both groups.
SYNE1 gene variant rs36215567 (NM_182961.4: c.20396+22A>G) occurs with a significantly higher incidence in the studied group when compared to the control population with OR 4.80 95%CI 1.43-14.45 (p=0.005) as well as when compared to the control population matched by age and gender OR 9.31 95%CI 1.64-95.41 (p=0.004). There were no statistically significant differences in the incidence of variants related to familial hypercholesterolemia such as LDLR c.667G>A, PCSK9 c.658-36G>A, and APOB c.12382G>A between both cohorts.
Conclusion A novel variant of the SYNE1 gene is associated with myocardial infarction in young patients with a family history of premature atherosclerosis.
Lay summary
The wide use of genetic information to predict coronary artery disease (CAD) development and incidence, particularly important in young people, still requires investigation before clinical implementation.
A novel variant of the SYNE1 gene is associated with myocardial infarction (MI) in young patients with a family history of premature atherosclerosis.
Although, the role of SYNE1 in the maintenance of proper function of the cardiac muscles and coronary arteries remains still under examination the result of this study open a new opportunity to use the SYNE1 gene variant in genetic risks MI scores.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Grant No. 501-1-10-14-20 from the Centre of Postgraduate Medical Education, Warsaw, Poland.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants of the study provided written informed consent. The Ethical Committee of the Centre of Postgraduate Medical Education approved the study protocol. The investigation conforms to the principles outlined in the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data referred to in the manuscript are available at the authors.
